Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders

Bone Marrow Transplantation

Volumn 18, Issue 5, 1996, Pages 843-850

  Hassan, M ^a   Fasth, A ^b   Gerritsen, B ^c   Haraldsson, A ^c   Syruckova Z ^d   Van Den Berg, H ^c   Sandstrom M ^e   Karlsson, M ^e   Kumlien, S ^a   Vossen, J ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bone marrow transplantation; Busulphan; Inherited disorders; Leukemia; Pediatric; Pharmacokinetics

Indexed keywords

BUSULFAN;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONGENITAL DISORDER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG TOXICITY; FEMALE; HUMAN; LEUKEMIA; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SAMPLING; SCHOOL CHILD; THALASSEMIA; WISKOTT ALDRICH SYNDROME;

ABNORMALITIES; ADMINISTRATION, ORAL; ADOLESCENT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA;

EID: 10544237678     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
2. Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992; 10: 445-450.
3. Geller RB, Saral R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute non-lymphocytic leukemia. Blood 1989; 73: 2209-2218.
4. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
5. Blazar BR, Ramsay NKC, Kersey JH et al. Pretransplant conditioning with busulphan (Myleran) and cyclophosphamide for nonmalignant diseases. Transplantation 1985; 39: 597-603.
6. Lucarelli G, Galimberti M, Delfini C et al. Marrow transplantation for thalassemia following busulphan and cyclophosphamide. Lancet 1985; i: 1355-1357.
7. Parkman R, Rappeport JM, Hellman S et al. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. Blood 1984; 64: 852-857.
8. Vermylen C, Cornu G. Bone marrow transplantation in sickle cell anaemia. Blood Rev 1993; 7: 1-3.
9. Sanders JE and the Seattle Marrow Transplantation Team. The impact of marrow transplant preparative regimen on subsequent growth and development. Semin Hematol 1991; 28: 244-249.
10. Sanders JE and the long-term follow-up team. Endocrine problems in children after bone marrow transplant for hematologic malignancies. Bone Marrow Transplant 1991; 8 (Suppl.): 2-4.
11. Lu C, Braine HG, Kaizer H et al. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 1984; 68: 711-717.
12. Bandini G, Belardinelli A, Rosti G et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13: 577-581.
13. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
14. Hassan M, Öberg G, Bekassy AN. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
15. Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1030.
16. Regazzi MB, Locatelli F, Buggia I et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 1993; 53: 45-52.
17. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
18. Yeager AM, Wagner JE Jr, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
19. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357-2362.
20. Hobbs JR, Hugh-Jones K, Shaw PJ et al. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1986; 1: 201-208.
21. Shaw PJ, Hugh-Jones K, Hobbs JR et al. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1: 193-200.
22. Vassal G, Challine D, Koscielny S et al. Chronopharmacology of high-dose busulfan in children. Cancer Res 1993; 53: 1534-1537.
23. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18-25.
24. Hassan M, Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 1983; 277: 374-380.
25. Karlsson MO, Sheiner LB. The importance of modeling inter-occasion variability in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1993; 21: 735-750.
26. Mentré F, Mallet A. Handling covariates in population pharmacokinetics. Int J Biomed Comput 1994; 36: 25-33.
27. Hastie TJ, Tibshirani RJ (eds). Generalized Additive Models. Chapman and Hall: London, 1990.
28. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
29. Winters RS, Green OC. Irradiation-induced growth hormone deficiency: blunted growth response and accelerated skeletal maturation to growth hormone therapy. J Pediatr 1985; 106: 609-612.
30. Krivit W, Whitley CB, Chang P-N et al. Lysosomal storage diseases treated by bone marrow transplantation: review of 21 patients. In: Johnson L, Pochedly C (eds). Bone Marrow Transplantation in Children. Alan R Liss: New York, 1990.
31. Atkinson K, Biggs J, Noble G et al. Preparative regimens for bone marrow transplantation containing busulfan are associated with hemorrhagic cystitis and veno-occlusive disease, but a short duration of leukopenia and little oropharyngeal mucositis. Bone Marrow Transplant 1987; 2: 385-394.
32. Hassan M, Öberg G, Björkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
33. Hassan M, Ljungman P, Ringdén O. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
34. Eksborg S. Evaluation of method-comparison data. Clin Chem 1981; 27: 1311-1312.
35. Schuler U, Schroer S, Kühnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
36. Chattergoon DD, Koren GK, Saunders EF. Development of a limited sampling method (LSM) for calculation of area under the curve (AUC) of concentration of busulphan vs time in children undergoing bone marrow transplantation (BMT). Blood 1995; 86 (Suppl.): 940a.
37. Chattergoon DD, Koren GK, Saunders EF. A comparison of limited sampling methods (LSMs) for estimation of busulphan (BU) area under the curve (AUC) in children undergoing bone marrow transplantation (BMT). Blood 1995; 86 (Suppl.): 567a.
38. Ehrsson H, Eksborg S, Österborg A et al. Oral melphalan pharmacokinetics-relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 1989; 6: 151-154.
39. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327-336.
40. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
41. 11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 1992; 30: 81-85.
42. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls. Anticancer Res 1994; 14: 2363-2370.